The effects of blood pressure and lipid control on kidney allograft outcome.
Despite the improvement in short- and long-term kidney allograft survival in recent years, a significant number of grafts are lost because of chronic allograft nephropathy (CAN) or death secondary to cardiovascular disease (CVD). There is growing evidence that both hypertension and hyperlipidemia play important roles in the progression of CAN and CVD in kidney transplant recipients. Large, randomized, controlled studies to determine the optimal target levels for BP and serum lipids, as well as the choice of drug therapy, are lacking. However, based on the available data, we suggest that currently recommended target levels in non-transplant patients should also be used after transplantation. We believe that achieving these target levels for BP and serum lipids are of primary importance, and that the non-lipid-lowering effects of HMG-CoA reductase inhibitors might exert additional benefits in prolonging graft survival.